Skip to main content

Vor Bio to Participate in the JMP Securities Hematology and Oncology Summit

CAMBRIDGE, Mass., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in a fireside chat and host virtual 1x1 investor meetings at the JMP Securities Hematology and Oncology Summit.

JMP Securities Hematology and Oncology Summit
Fireside Chat: Tuesday, December 5, 2023 at 1:30 pm ET
Location: Virtual

About Vor Bio
Vor Bio is a clinical-stage cell and genome engineering company that aims to change the standard of care for patients with blood cancers by engineering hematopoietic stem cells to enable targeted therapies post-transplant. For more information, visit: www.vorbio.com.

Contact:

Media & Investors
Sarah Spencer
+1 857-242-6076
sspencer@vorbio.com


Primary Logo

Recent Quotes

View More
Symbol Price Change (%)
AMZN  246.01
-0.28 (-0.11%)
AAPL  258.80
-0.25 (-0.09%)
AMD  206.20
+1.52 (0.74%)
BAC  56.12
-0.05 (-0.10%)
GOOG  330.62
+4.61 (1.41%)
META  651.26
+5.20 (0.80%)
MSFT  477.35
-0.76 (-0.16%)
NVDA  185.00
-0.04 (-0.02%)
ORCL  196.69
+7.54 (3.99%)
TSLA  444.80
+9.00 (2.07%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.